Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of relapsed CBCC, CC and LPIC lymphoma with FCM chemotherapy alone or in combination with the monoclonal anti CD 20 antibody rituximab followed by anti-CD 20 maintenance or observation only

Next Previous
X
Search
Trial Profile

Treatment of relapsed CBCC, CC and LPIC lymphoma with FCM chemotherapy alone or in combination with the monoclonal anti CD 20 antibody rituximab followed by anti-CD 20 maintenance or observation only

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide; Fludarabine; Mitoxantrone; Rituximab
  • Indications Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 May 2021 Biomarkers information updated
    • 27 Jul 2007 The expected completion date for this trial is now 1 Dec 2008.
    • 22 Nov 2006 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top